Gosset
Book a demo

AAN Annual Meeting 2026: key results and trends

What the 3,275 abstracts at AAN Annual Meeting 2026 reported, drug by drug: the readouts that stood out and the targets and modalities that dominated, and how this edition compares with earlier years.

abstracts
3,275
7% more than 2025
drug-linked abstracts
1,138
companies
187
from Phase 3 studies
90

Drug-linked abstracts by phase

  • Phase 1 25
  • Phase 1/2 9
  • Phase 2 27
  • Phase 2/3 6
  • Phase 3 90
  • Phase 4 11

Key results

Quotes are taken verbatim from each abstract's results; selection is automated. Report an issue

  1. Phase 3Primary progressive multiple sclerosis (PPMS)Genentech

    ocrelizumab

    ORATORIO-HAND: Results of the Primary Analysis of Ocrelizumab vs Placebo in Primary Progressive Multiple Sclerosis, Including Older Patients and Those With More Advanced Disease

    The percentage of ocrelizumab and placebo patients with 12W-cCDP was 32.7% vs 40.4% (hazard ratio [HR] [95% CI]: 0.70 [0.57-0.86]; risk reduction [RR], 30%; P =0.0007); 16.7% vs 24.9% on 9HPT (RR, 41%; P=0.0002) and 23.0% vs 30.8% on EDSS (RR, 33%; P =0.0013).

    Read the abstract (opens in a new tab)

  2. Phase 3Tourette syndrome (TS)Emalex Biosciences

    ecopipam

    Efficacy and Safety of Ecopipam for Tourette Syndrome: Results from a Phase 3, Double-blind, Placebo-controlled, Randomized Withdrawal Trial

    The risk of relapse was significantly reduced in the ecopipam group compared with placebo in the pediatric (hazard ratio [HR]=0.5 [0.3, 0.8]; P=0.008) and pediatric plus adult (HR=0.5 [0.3, 0.8]; P=0.005) populations.

    Read the abstract (opens in a new tab)

  3. Phase 3Multiple sclerosis (MS)Sanofi

    tolebrutinib

    Effects of Tolebrutinib on Progression Independent of Relapse Activity in the Phase Three GEMINI Relapsing MS Trials

    Although tolebrutinib was not superior to teriflunomide in reducing ARR, the percentage of participants with 6mCDW was 8.3% with tolebrutinib and 11.3% with teriflunomide (hazard ratio, 0.71; 95% CI, 0.53–0.95).

    Read the abstract (opens in a new tab)

  4. Phase 3MigraineAbbVie

    atogepant

    Tolerability, Safety, and Efficacy of Atogepant Versus Topiramate in Participants Requiring Preventive Treatment for Migraine: Results from the Head-to-head TEMPLE Trial

    A higher proportion of participants experienced TEAEs with topiramate compared to atogepant (88.8% vs 76.9%).

    Read the abstract (opens in a new tab)

  5. Phase 3Narcolepsy type 1 (NT1)Takeda

    oveporexton

    The Radiant Light: Efficacy and Safety of Oveporexton (TAK-861), an Oral Orexin Receptor Two Agonist for the Treatment of Narcolepsy Type One

    The most common TEAEs with oveporexton were pollakiuria (43 [61.4%]) and insomnia (40 [57.1%]).

    Read the abstract (opens in a new tab)

  6. Phase 3Epilepsy

    cenobamate

    Efficacy and Safety of Adjunctive Cenobamate for the Treatment of Primary Generalized Tonic-clonic Seizures in Adults and Adolescents

    Among the 161 patients (placebo, n=78; cenobamate, n=83) analyzed during the maintenance-phase, the ≥50% responder rate was 71.1% for cenobamate (vs 51.3% placebo, P =0.01); 43.4% of cenobamate-treated patients were seizure-free (vs 20.5% placebo, P =0.002).

    Read the abstract (opens in a new tab)

  7. Phase 3Narcolepsy type 1 (NT1)Axsome Therapeutics

    reboxetine

    Impact of AXS-12 on Symptom Severity and Functional Impairment in Narcolepsy: Results From the Phase Three SYMPHONY Trial

    At week 5, AXS-12 significantly improved CGI-S versus placebo (LS mean difference [95% CI]=0.72 [0.29, 1.16]; p=0.001).

    Read the abstract (opens in a new tab)

  8. Phase 3Autoimmune Encephalitis (AE)

    immune globulin

    Phase 3 Clinical Study of IVIG for Efficacy and Safety in Patients with Autoimmune Encephalitis

    The proportion of responders was 57.1% (95% CI: 18.405, 90.101) in the IVIG group and 0% (95% CI: 0.000, 70.706) in the control group.

    Read the abstract (opens in a new tab)

  9. Phase 3Myasthenia gravis (MG)Regeneron Pharmaceuticals

    cemdisiran

    Rapid and Sustained Efficacy of Subcutaneously Administered Cemdisiran Without Complete Complement Blockade in Patients with Generalized Myasthenia Gravis (gMG): Primary Efficacy and Safety Results from the Phase Three NIMBLE Trial

    TEAEs occurred in 69.2% ( cemdisiran ), 81.3% (combination) , and 77.1% (placebo).

    Read the abstract (opens in a new tab)

  10. Phase 3MigraineTeva Pharmaceutical Industries

    fremanezumab

    Efficacy and Safety of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Children and Adolescents: Outcomes from Two Randomized, Double-blind, Placebo-controlled, Phase 3 Studies

    In the EM study, MHD reduction was significantly greater with fremanezumab versus placebo (–2.6 vs –1.5; p=0.0172), as was the ≥50% MMD response rate (47.2% vs 27.0%; p=0.0016).

    Read the abstract (opens in a new tab)

  11. Phase 3Parkinson's disease (PD)Bial

    opicapone

    Comparative Efficacy of Opicapone and Entacapone in the Management of Motor Fluctuations in Parkinson’s Disease

    A higher proportion of patients on OPC vs ENT showed minimally, much or very much improved Clinician (73% vs 50.9% respectively, p =0.0070) and Patient (72.1% vs 52.5% respectively, p =0.0091) Global Impression of Change scores.

    Read the abstract (opens in a new tab)

  12. Phase 3InsomniaEisai

    lemborexant

    Interpreting Adverse Events of Somnolence With Lemborexant in Clinical Trials

    Few participants discontinued due to somnolence (PBO: 0.6%; LEM5: 1.1%; LEM10: 2.3%); most TEAE-S were mild and transient.

    Read the abstract (opens in a new tab)

Small molecules, the most frequent modality, accounted for 62% of drug-linked abstracts, up from 58% in 2025. Carbohydrate, lipid and polymer therapeutics (1%) were new to the top modalities compared with 2025. CD19 (2%) was new to the top targets compared with 2025.

What the abstracts covered

Share of the 1,138 drug-linked abstracts, by the target, modality, disease and company of each drug. An abstract can count in more than one row, so a list can add up to more than 100%.

Top targets

  1. GR807%
  2. FCGRT757%
  3. CD20636%
  4. C1Q504%
  5. FcγR494%
  6. PLG464%
  7. NaV303%
  8. DDC262%
  9. DRD262%
  10. CD19New252%

Top modalities

  1. Small molecules70962% from 58% in 2025
  2. Monoclonal antibodies32529%
  3. Non-antibody therapeutic proteins948%
  4. Blood, tissue and cell-derived products797%
  5. Peptides333%
  6. Cell therapies252%
  7. Oligonucleotide and RNA therapeutics202%
  8. Carbohydrate, lipid and polymer therapeuticsNew171%

Top diseases

  1. Ischemic stroke11210%
  2. Alzheimer's disease (AD)686%
  3. Multiple sclerosis (MS)666%
  4. Myasthenia gravis (MG)646%
  5. Parkinson's disease (PD)585%
  6. Epilepsy545%
  7. Migraine414%
  8. Neuromyelitis Optica Spectrum Disorder (NMOSD)363%
  9. Chronic inflammatory demyelinating polyneuropathy (CIDP)303%
  10. Autoimmune Encephalitis (AE)282%

Most active companies

  1. Genentech1049%
  2. Pfizer857%
  3. ADMA Biologics484%
  4. Merck414%
  5. Bristol Myers Squibb353%
  6. GSK353%
  7. UCB313%
  8. Eisai293%
  9. Roche282%
  10. argenx252%

AAN over the years

  1. 20263,275 abstracts · this edition
  2. 20253,066 abstracts

Explore every AAN 2026 result in Gosset

All 1,138 drug-linked abstracts, joined to each drug’s trials, targets, developers and deals, with a source behind every line.

This page shows a sample of results. Gosset has the abstracts from this meeting and 100+ others; reach out for full access.

Get full accessExplore the results in Gosset

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call